US FDA Approves First Tumor-agnostic HER2-directed Therapy
The US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read moreThe US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreIn a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read moreEisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read morePharma giant Pfizer and American biotech company Seagen officially announced on Monday that they have reached a conditional merger agreement
Read moreThe CTAT Enzymatic Antibody Drug Conjugation Technology -Benefits for Diagnostic Applications and ADC’s for Oncology. A EUCODIS Bioscience Case Study
Read moreDarmstadt headquartered Merck KGaA, a leading science and technology company operating in the U.S. & Canada as MilliporeSigma, has announced a
Read more